IGM Biosciences Inc
NASDAQ:IGMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Castellana Properties Socimi SA
MAD:YCPS
|
ES |
|
M
|
Mitra Komunikasi Nusantara Tbk PT
IDX:MKNT
|
ID |
|
T
|
Turn Therapeutics Inc
NASDAQ:TTRX
|
US |
|
Chubb Ltd
NYSE:CB
|
CH |
|
A
|
AjinExTek Co Ltd
KOSDAQ:059120
|
KR |
|
Zhejiang Tiantie Industry Co Ltd
SZSE:300587
|
CN |
IGM Biosciences Inc
Research & Development
IGM Biosciences Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IGM Biosciences Inc
NASDAQ:IGMS
|
Research & Development
-$95m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
IGM Biosciences Inc
Glance View
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
See Also
What is IGM Biosciences Inc's Research & Development?
Research & Development
-95m
USD
Based on the financial report for Jun 30, 2025, IGM Biosciences Inc's Research & Development amounts to -95m USD.
What is IGM Biosciences Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-13%
Over the last year, the Research & Development growth was 51%. The average annual Research & Development growth rates for IGM Biosciences Inc have been 16% over the past three years , -13% over the past five years .
